CD8A and ovarian carcinoma: Considering that humoral immune response to NY-ESO-1 is tightly associated with specific CD8+ and CD4+ T cell responses against the antigen [41, 50], our results suggest that high-frequencies of dominant TAA-specific T-cell clones present at the time of diagnosis are clinically relevant for mediating improved survival of ovarian cancer patients.